2014
DOI: 10.1155/2014/540451
|View full text |Cite
|
Sign up to set email alerts
|

Nucleic Acid Aptamers: Research Tools in Disease Diagnostics and Therapeutics

Abstract: Aptamers are short sequences of nucleic acid (DNA or RNA) or peptide molecules which adopt a conformation and bind cognate ligands with high affinity and specificity in a manner akin to antibody-antigen interactions. It has been globally acknowledged that aptamers promise a plethora of diagnostic and therapeutic applications. Although use of nucleic acid aptamers as targeted therapeutics or mediators of targeted drug delivery is a relatively new avenue of research, one aptamer-based drug “Macugen” is FDA appro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
50
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 75 publications
(56 citation statements)
references
References 95 publications
(116 reference statements)
1
50
0
Order By: Relevance
“…Aptamers, for example, are small molecules with either nucleic acid or peptide structure that bind specific ligands, created by an in vitro affinity selection among a large amount of random sequences. [170] Due to their size advantage, there is an increasing interest on them in the FET community, as demonstrated by the large amount of ultrasensitive silicon nanowire-based aptasensors developed during the last years for detection of neuronal potassium ion efflux [57] (Figure 10b), dopamine [171] (Figure 10c), thrombin, [52] PSA, [172] and antivascular endothelial growth factor (VEGF) [173] among others. [170] Due to their size advantage, there is an increasing interest on them in the FET community, as demonstrated by the large amount of ultrasensitive silicon nanowire-based aptasensors developed during the last years for detection of neuronal potassium ion efflux [57] (Figure 10b), dopamine [171] (Figure 10c), thrombin, [52] PSA, [172] and antivascular endothelial growth factor (VEGF) [173] among others.…”
Section: Small Receptorsmentioning
confidence: 99%
“…Aptamers, for example, are small molecules with either nucleic acid or peptide structure that bind specific ligands, created by an in vitro affinity selection among a large amount of random sequences. [170] Due to their size advantage, there is an increasing interest on them in the FET community, as demonstrated by the large amount of ultrasensitive silicon nanowire-based aptasensors developed during the last years for detection of neuronal potassium ion efflux [57] (Figure 10b), dopamine [171] (Figure 10c), thrombin, [52] PSA, [172] and antivascular endothelial growth factor (VEGF) [173] among others. [170] Due to their size advantage, there is an increasing interest on them in the FET community, as demonstrated by the large amount of ultrasensitive silicon nanowire-based aptasensors developed during the last years for detection of neuronal potassium ion efflux [57] (Figure 10b), dopamine [171] (Figure 10c), thrombin, [52] PSA, [172] and antivascular endothelial growth factor (VEGF) [173] among others.…”
Section: Small Receptorsmentioning
confidence: 99%
“…15 cycles), the sequences obtained are cloned, sequenced and their binding affinity, secondary structure and Gibbs energy are evaluated in order to select the aptamers with high affinity and specificity to the target molecule (Darmostuk et al, 2015;Dua et al, 2011;Radom et al, 2013;Santosh and Yadava, 2014;Song et al, 2012;Syed and Pervaiz, 2010;Vikesland and Wigginton, 2010). The specific properties of aptamers as bioreceptors in the development of aptasensors offer some advantages over methods that are mainly based on standard affinity receptors (e.g.…”
Section: Aptamer-based Biosensors: Aptasensorsmentioning
confidence: 99%
“…To date, a large variety of aptamers had been developed through SELEX technology, including aptamers targeting small molecules (such as dyes, metal ions, amino acids, and short peptides), biologic macromolecules (nucleic acids and proteins), molecular complexes, viruses, bacteria, live cells, and whole organisms [20][21][22][23][24][25]. Aptamers combine nanomolar range targetbinding affinities with exquisite target specificity, which makes them a versatile tool for diagnostics, in vivo imaging, and targeted therapeutics [12,[26][27][28][29]. Moreover, compared to protein antibodies, aptamers offer unparalleled advantages, as they can be chemically synthesized through a simple process, modified with a variety of functional groups and/or imaging reporters, and elicit little to no immunogenicity or toxicity in preclinical studies [30][31][32][33][34].…”
Section: Introductionmentioning
confidence: 99%